August 4, 2025

Figure S2 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy

View Full Paper

Ask AI

Bookmark

The research focuses on high-risk pediatric cancers using zebrafish models for testing potential therapies.
A 125-drug library was screened in patient-derived samples to evaluate drug responses effectively.
High-throughput screening techniques were employed to facilitate rapid analysis of drug efficacy.
This work advances understanding of precision therapy, aiming to improve treatment outcomes for children with cancer.

Implication

Ex vivo screening reveals drug responses in patient-derived samples, suggesting pathways for precision therapy in pediatric cancers.

Ex vivo single agent high-throughput screening of a 125-drug library in patient-derived samples.

No takes yet. Share an insight, caveat, or question.

Azzam et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Ex vivo screening reveals drug responses in patient-derived samples, suggesting pathways for precision therapy in pediatric cancers.

Ex vivo single agent high-throughput screening of a 125-drug library in patient-derived samples.